The Banc de Sang i Teixits (Blood and Tissue Bank, BST) cooperates with the Haemophilia Unit at the Vall d'Hebron University Hospital to help persons with congenital coagulopathy.
This unit is considered the leading centre in Catalonia for the comprehensive treatment of patients suffering from congenital haemorrhagic coagulopathies such as haemophilia, Von Willebrand disease, thrombopathies and other blood clotting disorders.
Congenital coagulopathies are rare and complex diseases that can only be treated efficiently within a comprehensive treatment programme offered by a multidisciplinary team of medical professionals.
The BST handles treatment coordination with the hospital unit and relations with other institutions and organisations through the medical coordinator. The Haemophilia Unit currently offers a wide range of services to meet all of the patients' needs and provide holistic care. The BST also assists the unit with the odontology services it provides.
In addition to clinical diagnosis, the BST supplies blood derivatives to treat these diseases, particularly FVIII concentrates for haemophilia A, FIX concentrates for haemophilia B and FVIII-FVW concentrates for treating Von Willebrand disease.
This division of the BST also includes a laboratory dedicated to the genetic study of congenital coagulopathy. This laboratory, which is fully involved in the research pursued at the BST, has had a twofold mission since it was created in 1998:
To support the diagnosis of congenital blood clotting disorders and other hereditary diseases; and to research and develop new diagnostic and therapeutic possibilities.
In the spirit of public service that characterises the BST, the Congenital Coagulopathy Division provides training for professionals with an interest in genetics and molecular diagnosis and is very active in the field of research.
The division's research primarily focuses on studying hereditary blood disorders or diseases of particular clinical, economic and social significance. One of the division's top priorities at present is innovating in technological tools and incorporating them into the laboratory routine. This allows us to conduct a more in-depth molecular study of blood clotting disorders by designing advanced protocols based on an analysis of the population's mutational spectrum. As a result, the division is able to offer highly informative genetic consulting services and perfectly safe antenatal diagnoses.
Many of the laboratory's results in recent years, with obviously important implications for both the health care industry and research, are related to molecular population analyses.
In order to share and publicise these results we created Hemobase, the first register of mutations characterized in haemophiliacs and patients with Von Willebrand disease in the Spanish population.
Hemobase includes educational contents as well as an advanced search system for accessing statistical data that can be used to relate specific clinical and molecular parameters. It is effectively an open database and a significant source of information on the relationship between the mutations that cause haemophilia and other blood clotting disorders and the resulting phenotypes, thus providing a better understanding of the molecular mechanisms involved in the progression of these diseases.